Omeros (NASDAQ:OMER) Earns "Strong-Buy" Rating from WBB Securities

Key Points

• Omeros has received a "strong-buy" rating from WBB Securities with a target price of $45.00, indicating a potential upside of 328.86% from its current stock price.
• The company's stock price has seen significant volatility, with a recent increase of 155.9%, reaching $10.49 on a trading volume much higher than its average.
• Despite the positive outlook from some analysts, the stock has mixed ratings overall, with two "strong buys," three "buys," two "holds," and one "sell" from various research firms.

Omeros (NASDAQ:OMER - Get Free Report)'s stock had its "strong-buy" rating reaffirmed by WBB Securities in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $45.00 price objective on the biopharmaceutical company's stock. WBB Securities' price target would suggest a potential upside of 328.86% from the company's current price.

Other research analysts have also issued research reports about the company. D. Boral Capital reiterated a "buy" rating and issued a $36.00 price target on shares of Omeros in a research report on Wednesday. HC Wainwright reiterated a "buy" rating and issued a $9.00 price target on shares of Omeros in a research report on Friday, June 27th. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research note on Friday, August 15th. Wall Street Zen raised shares of Omeros from a "sell" rating to a "hold" rating in a research note on Saturday, September 20th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Omeros in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $27.50.

Omeros Stock Up 155.9%

OMER traded up $6.39 on Wednesday, hitting $10.49. The company had a trading volume of 83,900,598 shares, compared to its average volume of 1,303,773. The company has a market cap of $714.15 million, a PE ratio of -4.83 and a beta of 2.32. Omeros has a 12-month low of $2.95 and a 12-month high of $13.60. The business's fifty day simple moving average is $4.24 and its 200 day simple moving average is $4.50.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.02. The company had revenue of $28.60 million during the quarter, compared to analysts' expectations of $0.31 million. On average, analysts anticipate that Omeros will post -3.09 earnings per share for the current fiscal year.

Institutional Trading of Omeros

Several institutional investors and hedge funds have recently modified their holdings of the stock. Deutsche Bank AG raised its stake in shares of Omeros by 4.9% during the first quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company's stock valued at $345,000 after acquiring an additional 1,973 shares in the last quarter. Brighton Jones LLC raised its stake in Omeros by 11.3% in the first quarter. Brighton Jones LLC now owns 30,714 shares of the biopharmaceutical company's stock worth $252,000 after buying an additional 3,125 shares in the last quarter. Harbour Investments Inc. raised its stake in Omeros by 51.9% in the first quarter. Harbour Investments Inc. now owns 9,218 shares of the biopharmaceutical company's stock worth $76,000 after buying an additional 3,149 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Omeros by 2.2% in the first quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company's stock worth $1,242,000 after buying an additional 3,321 shares in the last quarter. Finally, Cypress Capital Group raised its stake in Omeros by 20.7% in the second quarter. Cypress Capital Group now owns 42,000 shares of the biopharmaceutical company's stock worth $126,000 after buying an additional 7,200 shares in the last quarter. Institutional investors own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.